Teva Pharmaceutical Industries Limited (TEVA)

Market Cap	38.73B +104.0%
Revenue (ttm)	17.35B +4.4%
Net Income	1.57B
EPS	1.34
Shares Out	1.16B
PE Ratio	25.53
Forward PE	14.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,750,424
Open	34.35
Previous Close	34.19
Day's Range	33.07 - 34.95
52-Week Range	14.99 - 37.35
Beta	0.85
Analysts	Strong Buy
Price Target	41.27 (+24.08%)
Earnings Date	Apr 29, 2026

About TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1901
• Employees: 33,950
• Stock Exchange: NYSE
• Ticker Symbol: TEVA
• Website: https://www.tevapharm.com

Analyst Summary

According to 13 analysts, the average rating for TEVA stock is "Strong Buy." The 12-month stock price target is $41.27, which is an increase of 24.08% from the latest price.

Price Target

$41.27

(24.08% upside)

Analyst Consensus: Strong Buy